![PDF) A “three-eyed” infant: A case of partial facial duplication (diprosopus monocephalus triophthalmos) PDF) A “three-eyed” infant: A case of partial facial duplication (diprosopus monocephalus triophthalmos)](https://www.researchgate.net/profile/Yusuf-Lawal/publication/321749995/figure/fig3/AS:578452982910976@1514925346486/Axial-computed-tomography-scan-brain-window-showing-a-duplicated-globe-within-the-left_Q320.jpg)
PDF) A “three-eyed” infant: A case of partial facial duplication (diprosopus monocephalus triophthalmos)
![Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13023-021-01968-1/MediaObjects/13023_2021_1968_Fig2_HTML.png)
Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb
Cost-effectiveness of sapropterin dihydrochloride (Kuvan®) for the treatment of hyperphenylalaninaemia (HPA) in adults and paed
![Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13023-021-01968-1/MediaObjects/13023_2021_1968_Fig1_HTML.png)
Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb
![A “three-eyed” infant: A case of partial facial duplication (diprosopus monocephalus triophthalmos) Yahaya RS, Suwaid MA, Hassan S, Lawal Y, Hassan I, Gwaram BA, Yahaya HB - West Afr J Radiol A “three-eyed” infant: A case of partial facial duplication (diprosopus monocephalus triophthalmos) Yahaya RS, Suwaid MA, Hassan S, Lawal Y, Hassan I, Gwaram BA, Yahaya HB - West Afr J Radiol](https://www.wajradiology.org/articles/2018/25/1/images/WestAfrJRadiol_2018_25_1_79_220627_f4.jpg)